TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26525473
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine solution (group 3)
Study: 11128825
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid effervescent 1000 mg
Study: 31147972
Drug: Initial loading
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial loading dose of 0.6 μg kg‐1 dexmedetomidine, followed by continuous infusion of 0.2 μg kg‐1 h‐1 (Group D, n=25)
Study: 19085526
Drug: Internet‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet‐ and email‐based treatment programme for social phobia (Shyness programme)
Study: 19085526
Drug: Cost-effectiveness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effectiveness of Internet treatment
Study: 16335199
Drug: Plum-blossom needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plum-blossom needle therapy combined with cupping
Study: 9808914
Drug: Saffron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (50 mg dissolved in 100 ml of milk, administered twice a day)
Study: 7695315
Drug: Quinine-clindamycin combination
Normalized name: clindamycin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine-clindamycin combination regimen
Study: 7695315
Drug: Quinine-doxycycline combination
Normalized name: quinine, combinations with psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine-doxycycline combination regimen
Study: 7695315
Drug: Quinine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine monotherapy
Study: 37852
Drug: Oxprenolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (20 mg)
Study: 21771709
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy with irinotecan, oxaliplatin, and cetuximab
Study: 17086891
Drug: Modified-release clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release clarithromycin 1000mg once daily (AECMR)
Study: 17086891
Drug: Immediate-release clarithromycin
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release clarithromycin 500mg twice daily (AECIR)
Study: 16343235
Drug: TEC (Epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEC (Epirubicin 60 mg/m² iv + Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Study: 16343235
Drug: TC (Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (Paclitaxel 175 mg/m² 3 h iv + Carboplatin AUC 5)
Study: 2149704
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 200 mg/day for 6 months
Study: 29086063
Drug: Glasdegib 100
Normalized name: glasdegib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib 100 mg diHCl formulation (fasted)
Study: 29086063
Drug: Glasdegib 100
Normalized name: glasdegib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib 100 mg small-particle size maleate formulation (fasted)
Study: 29086063
Drug: Glasdegib 100
Normalized name: glasdegib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib 100 mg large-particle size maleate formulation (fed)
Study: 29086063
Drug: Glasdegib 100
Normalized name: glasdegib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib 100 mg large-particle maleate formulation (fasted) with rabeprazole
Study: 29086063
Drug: Glasdegib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib 50 mg oral solution (fasted)
Study: 12952499
Drug: ABI 007
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI 007 260 mg/m(2) administered as a 30-minute infusion without steroid pretreatment
Study: 12952499
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m(2) administered over 3 hours with steroid pretreatment
Study: 11023500
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy and autografting
Study: 1423182
Drug: GMCSF administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMCSF administered subcutaneously (SC) at 5 micrograms/kg twice daily for 14 days starting the day after chemotherapy
Study: 1423182
Drug: GMCSF administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMCSF administered SC at 10 micrograms/kg daily for 20 days starting 2 days after chemotherapy
Study: 1423182
Drug: GMCSF administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMCSF administered SC every 12 hours for 14 days
Study: 1423182
Drug: Prechemotherapy priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prechemotherapy priming with GMCSF twice daily for 4 days (days -6 to -3)
Study: 1423182
Drug: GMCSF administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMCSF administered SC at 5 micrograms/kg twice daily
Study: 1423182
Drug: Moderate-dose GMCSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose GMCSF with antihistamines and ibuprofen
Study: 6374679
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g nabumetone twice daily
Study: 30386143
Drug: LVLC-CTU (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVLC-CTU (80 kVp and 240 mgI/mL) with IR
Study: 30386143
Drug: Conventional CTU
Normalized name: ACCESS,ADAPTER CHAIT C#CTU-10.0-18-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CTU (120 kVp and 350 mgI/mL) with filtered-back projection
Study: 27154481
Drug: Shared decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared decision-making (SDM) via a multifaceted strategy (decision aid, support of IVF nurse, reimbursement for an extra treatment cycle)
Study: 22629840
Drug: 89Sr-chloride fractional
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Sr-chloride fractional injection (50 Mbk)
Study: 22629840
Drug: Standard 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 150 Mbk injection (Control)
Study: 20558431
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aliskiren and Valsartan
Study: 20558431
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy (Aliskiren, Valsartan, Combination)
Study: 18377854
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia intervention 20 minutes before and throughout the surgical procedure
Study: 18377854
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia intervention
Study: 12823307
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine for confirmed dermatophyte onychomycosis for 12 weeks
Study: 11880064
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (PPS) therapy at doses of 300, 600, or 900 mg/day for 32 weeks
Study: 10025931
Drug: HCQ 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ 400 mg/day
Study: 10025931
Drug: HCQ 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ 800 mg/day
Study: 10025931
Drug: HCQ 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCQ 1200 mg/day
Study: 10025931
Drug: Naproxen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1,000 mg/day)
Study: 7546934
Drug: High-dose botulinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose botulinum toxin type A (240 units/session)
Study: 7546934
Drug: Medium-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose botulinum toxin type A (120 units/session)
Study: 7546934
Drug: Low-dose botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose botulinum toxin type A (60 units/session)
Study: 6452842
Drug: Ipratropium nasal
Normalized name: ipratropium nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium nasal spray (80 micrograms, 4 times daily for 1 week)
Study: 24072451
Drug: Dronedarone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronedarone (400 mg twice daily)
Study: 18594127
Drug: Medio/Lateral (M/L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medio/Lateral (M/L) training
Study: 15220949
Drug: Trans fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans fatty acids (TFA) - 33 g daily intake from partially hydrogenated soy oil containing 20 g of TFA
Study: 15220949
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFA) - 33 g daily intake from fish oil with approximately 4 g of n-3 PUFA
Study: 15220949
Drug: Control fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control fat - 33 g daily intake of control fat
Study: 9924276
Drug: Control +
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control + 50 g sugarbeet fibre/d
Study: 9924276
Drug: Control +
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control + 50 g commercial inulin/d
Study: 29747834
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg folic acid + 10 mg enalapril
Study: 27622219
Drug: Omega-3 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (1000 mg capsules for 6 months)
Study: 20573635
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg (2 doses: 2 h before surgery and on first postoperative day)
Study: 10868864
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg) plus Metformin (500 mg)
Study: 9268758
Drug: Itraconazole 300
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 300 mg/day (Group 1)
Study: 9268758
Drug: Itraconazole 300
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 300 mg/day followed by cryosurgery (Group 3)
Study: 3955536
Drug: Beta-carotene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (180 mg/week for 16 weeks)
Study: 3955536
Drug: Beta-carotene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (180 mg/week for 16 weeks) plus vitamin A (100,000 IU/week for 16 weeks)
Study: 3046484
Drug: Cephalexin hydrochloride
Normalized name: Cephalexin Hydrochloride
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin hydrochloride (250 mg four times a day) in study A
Study: 3046484
Drug: Cephalexin monohydrate
Normalized name: Cephalexin Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin monohydrate (500 mg two times a day) in study A
Study: 3046484
Drug: Cephalexin hydrochloride
Normalized name: Cephalexin Hydrochloride
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin hydrochloride (500 mg two times a day) in study B
Study: 3046484
Drug: Cephalexin monohydrate
Normalized name: Cephalexin Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin monohydrate (250 mg four times a day) in study B
Study: 3046484
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (cephalexin hydrochloride and cephalexin monohydrate)
Study: 19916311
Drug: Air-ozone baths
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air-ozone baths (20 minutes, ozone concentration 8-10 mg/l, temperature 36 degrees C, 10 daily procedures)
Study: 19916311
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30 patients without operational treatment)
Study: 7580021
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of hMG (75 IU/day) in desensitization protocol
Study: 7580021
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of hMG (75 IU/day) in flare-up protocol
Study: 27036360
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (40mcg/day per nostril) intranasal spray for 6 months, starting at postoperative week 3 after wound healing
Study: 27036360
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline spray
Study: 25539418
Drug: Nobori drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nobori drug-eluting stent
Study: 25539418
Drug: TAXUS drug-eluting
Normalized name: Taxus baccata fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAXUS drug-eluting stent
Study: 23809343
Drug: Surfactant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant therapy (given prophylactically or in established RDS)
Study: 10830075
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (15 ml ropivacaine 7.5 mg/ml with fentanyl 100 micrograms)
Study: 2004920
Drug: Heparin 4
Normalized name: heparin 40000 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 4 U/ml in 0.9% sodium chloride
Study: 6192514
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin combined with dihydroergotamine
Study: 30415637
Drug: Marine n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n-3 fatty acids (1 g per day)
Study: 26291629
Drug: Telephone and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone and in‐person cognitive‐behavioral therapy
Study: 24064511
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg IC43 with adjuvant
Study: 24064511
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg IC43 with adjuvant
Study: 24064511
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg IC43 with adjuvant
Study: 24064511
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg IC43 without adjuvant
Study: 22511052
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy containing doxycycline (Group A): esomeprazole 20 mg, bismuth potassium citrate 220 mg, amoxicillin 1 g, doxycycline 100 mg, all bid for ten days.
Study: 22511052
Drug: Routine quadruple
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine quadruple therapy (Group B): esomeprazole 20 mg bid, bismuth potassium citrate 220 mg bid, metronidazole 400 mg bid, tetracycline 750 mg q.6h, for ten days.
Study: 12529345
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy immediately following surgery
Study: 12529345
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant chemotherapy until clinically indicated
Study: 10374092
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue treatment (3 cycles prior to surgery)
Study: 1423177
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg orally daily for 2 years
Study: 1423177
Drug: PSK 3
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PSK 3 g orally daily for 2 years
Study: 1423177
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with mitomycin C (MMC) and ftorafur (FT)
Study: 6431470
Drug: Naloxone (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.7 to 1.0 micrograms/kg/min, total dose 8.8‐13.2 mg)
Study: 6431470
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 mg intramuscularly before sleep onset)
Study: 15152279
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medical treatment)
Study: 25052698
Drug: Idarubicin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin at a maximum-tolerated dose (MTD) of 16 mg/m² IV on day 1, combined with high-dose methotrexate (3 g/m² IV), vindesine (3 mg/m² IV), and prednisolone (60 mg/m² IV/orally) on days 1-5.
Study: 15627809
Drug: Slow-release caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release caffeine (SRC) 300 mg twice a day
Study: 12435461
Drug: Systemic lidocaine
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic lidocaine (2mg/kg bolus for 5 min followed by 2mg/kg/h infusion for 40 min)
Study: 12435461
Drug: Cumulative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doses of systemic lidocaine (0.5-2mg/kg) injected 30 min after incision
Study: 25043647
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (a nitric oxide donor) given for seven days
Study: 25043647
Drug: Continuing pre-stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing pre-stroke antihypertensive therapy
Study: 25043647
Drug: Stopping (temporarily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping (temporarily for seven days) pre-stroke antihypertensive drugs
Study: 16401155
Drug: High-dose divalproex
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose divalproex
Study: 16401155
Drug: Low-dose divalproex
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose divalproex
Study: 12771535
Drug: High-flux dialyzers
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flux dialyzers (e.g. cellulose triacetate, polymethylmethacrylate) or hemodiafiltration
Study: 8610383
Drug: Pentoxifylline (PTF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTF) 800 mg q 8 hr for at least 24 h
Study: 1467165
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (CIV) of morphine
Study: 1467165
Drug: Intermittent parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent parenteral opioids (IPO)
Study: 1467165
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation (50% O2)
Study: 6369238
Drug: Phenobarbital treatment
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital treatment (two loading doses of 10 mg/kg 12 hours apart, followed by a maintenance dose of 2.5 mg/kg every 12 hours for 6 days)
Study: 29765213
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 μg once-daily add-on therapy
Study: 20228999
Drug: Propofol continuous
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol continuous infusion (0.8 mg/kg induction dose and 3 mg/kg/h maintenance dose)
Study: 20228999
Drug: Intermittent midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermittent midazolam injection (mean total dose 10.3 +/- 4.5 mg)
Study: 15602505
Drug: Low-dose liquid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose liquid fluoxetine (mean final dose: 9.9±4.35 mg/day)
Study: 15602505
Drug: Liquid fluoxetine
Normalized name: fluoxetine Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid fluoxetine
Study: 27502323
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACT) guided by the 15-gene expression signature
Study: 27502323
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACT) guided by clinical stage
Study: 17953678
Drug: Neutral pH
Normalized name: Gelato Neutral pH 2 % Oral Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral pH superoxidised aqueous solution (NpHSS)
Study: 12429535
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment starting at 7.5 mg/week, increased to a maximum of 25 mg/week if necessary
Study: 402671
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (imipramine and amitriptyline)
Study: 23889217
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (3 tablets daily of 25 mg micronized DHEA for at least 12 weeks) in young women under 40 years
Study: 23889217
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (3 tablets daily of 25 mg micronized DHEA for at least 12 weeks) in women over 40 years
Study: 23080088
Drug: Drug Eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Eluting Stent (DES) - Paclitaxel eluting stent (Chopin Luc(TM), Balton, Poland)
Study: 19032573
Drug: Nicotine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.5 mg/kg s.c.) administered via 10 injections every second day starting from postnatal day 27 for adolescents and day 75 for adults.
Study: 19032573
Drug: Nicotine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.5 mg/kg) administered to challenge animals after initial treatment.
Study: 15009842
Drug: Azithromycin (5-days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5-days treatment)
Study: 15009842
Drug: Metronidazole (7-days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (7-days treatment)
Study: 11152432
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of azithromycin (1.5 g)